Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

Stopped early · Not applicable

Conditions studied: Chronic Phase CML

In brief

This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

Key facts

Study ID

NCT01490775

Run by

Rex Cancer Center, Raleigh, NC

People needed

27

Starts

2009-04-01

Expected to finish

2015-06-30

Last updated by the study team

2018-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 18 years of age or older.
• Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating physician has determined that treatment with imatinib or nilotinib is appropriate
• Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna (nilotinib) 300-400 mg twice daily
• Known performance status 0,1 or 2 (ECOG)
• Known adequate end organ function, defined as:
• Total bilirubin < 1.5 xULN SGOT and SGPT <2.5 x ULN ANC > 1.5 Platlets > 100,000
• Patient is willing and able to use a cell phone
• Written, voluntary informed consent

You may not qualify if…

• Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent

Where it is running

• Northwestern University — Chicago, Illinois, United States
• Rex Cancer Center - Wakefield — Raleigh, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.